News

MyoSpectrumNet pulls 3 public fundus datasets into 1 multi-output framework. Screening and grading accuracy held up against dedicated models.

ODs face a $32.63 Medicare conversion factor in 2027, plus 80% payment for the lower-cost service when an E/M visit and 0-day procedure share a date.

Luma, an eye-tracking and assessment tool, helps eye care professionals gain objective insights into visual performance.

Christopher Browning, OD, and Nicholas Garn, OD, now offer cataract surgery and refractive lens exchange in their own practices.

According to Raphael Rostenne, CTO of EyeCarePro, "anything that takes time" has the potential to frustrate patients, especially before they're in a practitioner's chair.

Now on EYE7 smart glasses, Eva goes beyond answering questions by reasoning about user needs and controlling vision-enhancement features.

Kansas, Tennessee, and Vermont expanded optometric scope in 2026, while vision plan reform and a proposed Medicare fee schedule cut affect practice management.

Bita Asghari, OD, FAAO, FSLS, discusses diagnosing ocular surface inflammation, recognizing atypical keratitis, and knowing when to refer to a cornea specialist.

The approval followed complete response letters tied to inspection and manufacturing issues.

Host Hamza Shah, OD, MS, FAAO, is joined by Melissa Barnett, OD, FAAO, FSLS, FBCLA, to discuss burnout among US optometrists, inspired by Abbott et al's nationwide survey.

From treating myopic complications to preventing them, eye care providers have ample opportunity to close a collaborative care gap.

This week’s top stories include pipeline updates in dry eye, retinitis pigmentosa, contact lens hygiene, and more.

The meeting, which comes a year after the agency issued a complete response letter in October 2025,2 was held from 8:30 am-3 pm ET and was open to public.

The licaminlimab trial enrolled 176 patients, two-thirds with a TNFR1 variant tied to stronger response. Data expected late 2026.

Nicole Haessly, OD, FAAO, discusses common unsafe contact lens habits, overlooked care steps, and how lens innovations have improved safety.

Amanda Nanasy, OD, discussed how sports can open the door to eye care for underserved athletes and what goes into her performance vision evaluations.

FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.

Raphael Rostenne discusses what a good phone call looks like and contributes to successful patient interactions with host Diana Canto-Sims, OD.

Amanda Nanasy, OD, described how her own concussion shaped her approach to athletes and why she ties every vision evaluation back to the demands of their sport.

Zachary Keaney, CPOA, discusses the lens care steps patients skip most often and why early diagnosis of lens-related keratitis is critical.

This week's top stories include breaking FDA approvals, insights on AI-assisted front desk management, and more.

Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using one tool consistently.

Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier time points.

CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.

Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.

Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.

Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.

Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.